Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $30.0 million.

  • Lineage Cell Therapeutics' Total Non-Current Liabilities was N/A to $23.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.7 million, marking a year-over-year change of. This contributed to the annual value of $30.0 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Total Non-Current Liabilities of $30.0 million as of FY2024, which was down 41.92% from $51.7 million recorded in FY2022.
  • In the past 5 years, Lineage Cell Therapeutics' Total Non-Current Liabilities registered a high of $83.6 million during FY2021, and its lowest value of $12.4 million during FY2020.
  • In the last 2 years, Lineage Cell Therapeutics' Total Non-Current Liabilities had a median value of $40.9 million in 2022 and averaged $40.9 million.
  • In the last 5 years, Lineage Cell Therapeutics' Total Non-Current Liabilities skyrocketed by 575.15% in 2021 and then tumbled by 38.14% in 2022.
  • Lineage Cell Therapeutics' Total Non-Current Liabilities (Yearly) stood at $12.4 million in 2020, then soared by 575.15% to $83.6 million in 2021, then tumbled by 38.14% to $51.7 million in 2022, then reached $30.0 million in 2024.